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Medicine, University of São Paulo, São Paulo, BrazilA B S T R A C TObjective: The objective of this study was to evaluate the burden of
malaria in Latin America and the Caribbean countries through a
systematic review and meta-analysis of published literature, gray
literature, and information from countries’ public health authorities
for the period 1990 to 2009. Methods: The random-effects meta-
analysis of the prospective studies, carried out in very highly endemic
areas, showed an annual incidence rate of 409.0 malaria episodes/
1000 person-years (95% conﬁdence interval [CI] 263.1–554.9), consid-
ering all ages, which was 40-fold the one estimated from areas with
passive surveillance only. Results: Overall, the most prevalent species
was Plasmodium vivax (77.5%; 95% CI 75.6–79.4) followed by Plasmodiumee front matter Copyright & 2015, International S
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tina.falciparum (20.8%; 95% CI 19.0–22.6) and Plasmodium malariae (0.08%;
95% CI 0.07–0.010). Data from regional ministries of health yielded an
estimated pooled crude annual mortality rate of 6 deaths/100,000
people, mainly associated with P. falciparum. Conclusion: This study
represents the ﬁrst systematic review of the burden of malaria in
Latin America and the Caribbean, with data from 21 countries.
Keywords: epidemiology, incidence, Latin America, malaria,
systematic reviews.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
It has been estimated that approximately 216 million malaria
cases and 655,000 deaths due to malaria occurred in 2010 world-
wide. Children from tropical developing countries are the most
burdened group [1,2]. To date, there are ﬁve identiﬁed species of
the malaria parasite causing malaria in humans (Plasmodium
falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malar-
iae, and Plasmodium knowlesi). P. vivax and P. falciparum are the
most commonly described in Latin America and the Caribbean
(LAC). P. vivax is prevalent in South and Central America, Middle
East, and India and accounted for 77% of all malaria cases
reported in 2011 in LAC. P. falciparum is the leading cause of
death worldwide from a single infectious agent [2] and is
predominantly found in tropical Africa, Southeast Asia, Oceania,
Haiti, parts of the Amazon basin of South America, and the
Dominican Republic. In fact, P. falciparum accounted for nearly all
cases of malaria in Haiti and the Dominican Republic [3].
Malaria transmission has been reported in nearly all LAC
countries, but it is highly variable across the LAC region and evenwithin countries [4]. The risk of malaria transmission is increased
in rural areas and ﬂuctuates seasonally in many locations, with
the highest transmission occurring at the end of the rainy season.
Approximately 3 of every 10 persons living in LAC are at risk for
malaria. In 2010, more than 675,000 cases were reported in 19
countries of the region [2]. A 2004 report from the World Health
Organization estimated the global disease burden of malaria to be
46.5 million disability-adjusted life-years, 111,000 of which cor-
responded to LAC, representing approximately 0.2% of the global
malaria burden [4,5]. Still, malaria constitutes a major public
health problem in LAC’s highest endemic areas. Currently,
although there is information regarding the burden of malaria
in the region [5], information regarding incidence, morbidity and
mortality, parasite species distribution, admission, and case-
fatality ratio (CFR) is scarce. Most available data come from public
health organizations and ministries of health and have not been
synthesized into a cohesive report.
The objective of this systematic review was to provide a
comprehensive epidemiological analysis of the malaria disease
burden in LAC.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Search Strategy
We conducted a systematic search including data from January
1990 to December 2009 using electronic databases included in
Cochrane CENTRAL and specialized registers of the Cochrane
Infectious Diseases Group, MEDLINE, EMBASE, and LILACS (see
Web Appendix 1 in Supplemental Materials found at http://dx.
doi.org.10.1016/j.vhri.2015.05.002). We also performed a search of
Internet search engines (Scholar Google, Tripdatabase, Scirus)
using keywords used for the electronic databases search. An
annotated search strategy for nonindexed “gray literature” was
used to obtain information from relevant sources for the same
period, such as reports from regional ministries of health, the Pan
American Health Organization (PAHO), the World Health Organ-
ization, institutional reports, special reports registered during
outbreaks, databases containing regional proceedings or con-
gresses’ annals, reference lists of included studies, and consult-
ing experts and associations related to the topic, according to a
protocol based on the Meta-analysis Of Observational Studies in
Epidemiology guidelines [6] and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses statement [7,8]. Authors
from selected articles were contacted to obtain missing or addi-
tional information when it was needed.Selection Criteria
We included data from control arms of randomized controlled
trials and from observational studies, including cohort, case-
control, surveillance, cross-sectional, and case-series studies
from the LAC region. There were no language restrictions. Studies
were included when at least 50 malaria cases were reported with
patients of any age. Prospective studies were included irrespec-
tive of the number of cases or endemicity but were meta-
analyzed if the follow-up was at least 6 months. We also included
studies reporting congenital malaria (diagnosed by ﬁnding para-
sites in the neonate within 7 days of birth). Data regarding health
resource consumption, such as length of hospitalization, use of
supportive care, number of surgical and physician visits, school
and work absenteeism, and reported direct costs per episode,
were also explored. Studies with patients’ enrolment before 1990,
reviews, letters or health economic evaluations without original
information, and studies not referring to LAC populations were
excluded. We also excluded studies focusing only on vector
epidemiology, antimalaric treatment and resistance, immunol-
ogy, asymptomatic population (according to PAHO deﬁnition) [9],
or malaria vaccines. A conﬁrmed malaria case was deﬁned as an
individual with a positive light microscopy, a rapid diagnostic
test, or other species elicitation technique (e.g., thin smear,
immune ﬂuorescence, polymerase chain reaction, enzyme-
linked immunosorbent assay, and other molecular technologies).
We planned separate analyses for gestational and congenital
malaria. We applied the term “hyperendemic” to areas where
transmission occurred throughout the year, at high intensity, and
the disease burden was high in young children [10].
Data on incidence, mortality, and distribution of parasite
species were obtained from PAHO and from ofﬁcial Ministry of
Health databases available electronically for Mexico, Colombia,
and Brazil [11–13]. The PAHO database did not include informa-
tion from Cuba and Chile because these countries do not show
malaria transmission [14]. If data were duplicated or data subsets
appeared in more than one publication, the principal investigator
was consulted and the study with larger sample size was used.
Outcome measures included incidence of malaria infection
using the Annual Parasitic Index (calculated as the number ofconﬁrmed cases per population at moderate and high risk: 1–10
cases and >10 cases, respectively, per 1000 people per year) [15],
hospitalization status, proportion of admissions attributable to
malaria, mortality, CFR, slides analyzed, percentage of positive
slides taken in health facilities, parasite species distribution, and
patterns of circulation of Plasmodium species strains over time.
We performed a meta-analysis of prospective studies that used
active surveillance, reporting on incidence of malaria episodes.
Screening and Data Abstraction
Two reviewers independently prescreened all identiﬁed citations
and selected studies, judging by title and abstract, that appeared
to be eligible for the review. Two reviewers then independently
evaluated full-text versions of all potentially eligible articles to
evaluate whether they met inclusion criteria. Any discrepancies
were resolved by consensus in both phases. Data were abstracted
using a previously piloted electronic chart.
Assessment of Risk of Bias
Three reviewers (A.B., A.C., and D.G.) independently evaluated
the quality of the methodology used in studies included in the
systematic review. The risk of bias of observational studies was
assessed by a modiﬁed checklist of essential items stated in
Strengthening the Reporting of Observational Studies in Epidemi-
ology and in Fowkes and Sanderson [16–20]. We used an algo-
rithm (see Web Appendix 2 in Supplemental Materials found at
http://dx.doi.org.10.1016/j.vhri.2015.05.002) to estimate a sum-
mary risk of bias considering six criteria (methods for selecting
study participants, methods for measuring exposure and out-
come variables, and methods to control confounding, design-
speciﬁc sources of bias and comparability among groups, stat-
istical methods, and declaration of conﬂict interests). Disagree-
ments were solved by consensus.
Statistical Analyses
Information coming from prospective studies was not combined
with ofﬁcial sources for meta-analysis and reported separately
because of observed heterogeneity in methodologies and subject
selection. To analyze our data, we conducted proportion meta-
analyses. We applied an arcsine transformation to stabilize the
variance of proportions (Freeman-Tukey variant of the arcsine
square-root of transformed proportions method). The pooled
proportion was calculated as the back-transformation of the
weighted mean of the transformed proportions, using inverse
arcsine variance weights for the ﬁxed- and random-effects
models. The estimates and their 95% conﬁdence interval (CI)
were calculated using the DerSimonian-Laird weights for the
random-effects model, in which signiﬁcant (470%) heterogeneity
between studies was found. We calculated the I2 statistic as a
measure of the proportion of the overall variation in the propor-
tion that was attributable to between-study heterogeneity. Stats-
direct version 2.7.9, Comprehensive Meta-analysis version
2.2.064, and STATA 9.0 were used for all analyses [21].Results
The search strategy identiﬁed a total of 4472 citations from
databases and 144 additional citations from the gray literature.
After revision of title and abstracts and the removal of duplicates,
3655 unique citations could be used. Of these, 3277 references
were excluded by title and abstract, 6 could not be retrieved in
full text, and 372 studies were potentially eligible and assessed by
full text (Fig. 1). A total of 64 studies were included; 24 reported
malaria incidence or provided information to estimate it (Table 1)
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3277 records excluded, not fulﬁlling 
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6 excluded, full-text not available 
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- 198 without primary informaon 
- 56 duplicate data 
- 21 <50 cases of malaria 
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- 10 Reviews or economic analyses 
- 4 dataset previous to 1990 
- 4 Not from LAC 
64 studies included for all outcomes.  
24 for malaria incidence (11 meta-analyzed) 
Fig. 1 – Flow diagram of studies.
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such as species distribution, diagnostic methods used, hospital-
izations, length of stay, and mortality (see Web Appendix 3 in
Supplemental Materials found at 10.1016/j.vhri.2015.05.002). Of
the 24 incidence studies, 11 were prospective with active case
detection. Most of the data found came from Brazil, Colombia,
Peru, and Ecuador. The main characteristics of the included
studies and their methodological quality assessment are pre-
sented in a table in Supplemental Materials (see Web Appendix 4
in Supplemental Materials found at: http://dx.doi.org.10.1016/j.
vhri.2015.05.002).
Incidence
In those studies that presented data by age (all 24 incidence
studies considered), children younger than 5 years had the
highest rate, at 325.8 malaria episodes (95% CI 50.4–601.2) and
adults (414 years old) showed an incidence rate of 50.6 episodes/
1000 person-years (95% CI 37.2–64.0) (Table 2). The random-
effects meta-analysis of the prospective studies carried out in
highly endemic areas showed an incidence rate of 409.0 malaria
episodes/1000 person-years (95% CI 263.1–554.9), considering all
ages (Table 2 and Fig. 2). The latter meta-analysis included 11
studies (13, counting substudies). Most areas meeting the deﬁ-
nition of “highly endemic” [46] are located in the Amazon basin.
The incidence of gestational malaria was 9.6 (8.3–10.9) cases/1000
pregnant women-year from the scarce studies identiﬁed in this
subgroup of patients [38,47,48]. We did not ﬁnd studies about the
incidence of congenital malaria.
The meta-analysis of data reported by public health author-
ities in LAC (also referred to as ofﬁcial data) showed that the
overall incidence rate for LAC in the study period was 10.4/1000
person-years (95% CI 10.3–10.6). This pooled ﬁgure includes areas
of high, medium, and low risk, and countrywide population
denominators, with all age groups considered. Fig. 3 shows a
map with quintiles of incidence from the meta-analytic estimates
from this ofﬁcial data. Suriname, French Guiana, and Guyanashowed the highest malaria incidence, with rates exceeding 60
episodes/1000 person-years. Argentina, the Dominican Republic,
El Salvador, Mexico, Panama, and Paraguay showed the lowest
incidences, less than 1 episode/1000 person-years. An analysis of
the yearly incidence (Fig. 4) showed a higher incidence during the
time period 1993 to 2000, with the highest incidence of 22.6
episodes/1000 person-years (95% CI 21.5–23.6) in 1994 and the
lowest of 5.7 (95% 5.1–6.2) in 2008. As expected, the I2 statistic
denoted a heterogeneity of greater than 80% in all analyses
performed.
Slide Positivity Rate and Species Distribution
Malaria slide positivity rate provides an alternative method for
estimating temporal changes in malaria incidence, and it has
been used in cross-sectional studies to deﬁne levels of endemic-
ity. Our results show a downward trend over the study period
(from 10% in 1990–1995 to o5% in 2007–2008). The overall
positivity rate for the study period from identiﬁed studies was
8.6 (95% CI 7.7–9.7) (data not shown).
The proportion of malaria cases by parasite species and by
country is presented in Table 3. Overall, the most prevalent
species was P. vivax (77.5%; 95% CI 75.6–79.4) followed by P.
falciparum (20.8%; 95% CI 19.0–22.6) and P. malariae (0.08%; 95%
CI 0.07-0.010). P. falciparum appeared to be more frequent in the
Dominican Republic, French Guiana, Haiti, and Suriname. In
Guyana, the number of cases due to P. vivax and P. falciparum
was similar, 47.8% and 50.4% of the cases, respectively (Table 3).
Species distribution, reported diagnostic methods, and resource
use outcomes by country can be found in Web Appendix 3 in
Supplemental Materials.
Mortality and CFR
The overall estimated malaria mortality rate from ofﬁcial sources
was 6/100,000 person-years. These sources rely on passive sur-
veillance from moderate-/high-risk areas. Suriname had the
Table 1 – Malaria published studies reporting incidence by country, LAC 1990–2009.
Country Location Reference Design Setting* Denominator Age
range
(y)
Admission
status
No. of
cases of
conﬁrmed
malaria
Incidence
(malaria
cases/1000
person-years)†
Starting/
ending
date
Duration
(mo)
Bolivia Amazon [22] Prospective
cohort
Low 622 p-y 414 72 116 Mar-2003/
Sep-2003
7
Brazil Amazon,
Rondhonia,
Portuchelo
[23] Cross-sectional High 157 All Outpatient 53 High Jun-1994/
Jun-1995
13
Brazil San Pablo,
Guaraparinga
[24] Prospective
cohort
Low 522 All Outpatient 106 192 May-
2000/Dec-
2002
32
Brazil Acre, Granada [25] Prospective
cohort
509 All 195 Medium Mar-2004/
May-2005
14
Brazil Leonislandia,
Peixoto
Azevedo
[26] Prospective
cohort
Low 187 All 101 539 Sep-1996/
Apr-1997
8
Brazil Amazon, Acre,
Rio Branco
[27] Cross-sectional High 38,470 414 Inpatient 445 Medium Jan-1996/
Dec-2001
72
Brazil Maranhão, San
Luis, Paraiso
[28] Cross-sectional Low 1,219 All Outpatient 129 72 Jan-1999/
Dec-2001
36
Brazil Rondônia,
Urupá
[29] Prospective
cohort
Low 840 All Outpatient 655 780 Jan-1991/
Dec-1996
12
Brazil Maranhã, São
Luis,
[30] Surveillance Low 217 All 106 0
Brazil Acrelandia,
Acre, Acre
[31] Prospective
cohort
High 467 All Outpatient 337 722 Jan-2004/
Apr-2004
2
Colombia Choco, Quibdo [32] Cross-sectional Low 144,494 All Outpatient 1053 3 Mar-1997/
Jul-1997
4
Colombia Bogota [33] RCT 57 17–27 19 333 Jun-2000/
Jul-2000
1, 5
Colombia Nariño, La Tola [34] Prospective
cohort
Low 810 (721 p-y) All 242 427 Feb-1991/
Feb-1992
12
Ecuador Esmeralda, La
Tola
[35] RCT Low 232 (198 p-y) 15–89 46 233 12
Ecuador Lower-Napo
region
[36] Surveillance Low 34,000 All Outpatient 1258 9 Jan-1992/
Dec-1995
48
French
Guiana
Camopi [37] Retrospective
cohort
Low 369 o5 676 935 Jan-2001/
Dec-2001
12
French
Guyana
[38] Cross-sectional High 3,788 All Inpatient 194 Medium Jan-1992/
Dec-1995
48
Guatemala Izabal, Izabal,
Los Amates
[39] RCT Low 341 All Outpatient 70 200 Sep-1990/
Aug-1991
12
Haiti [40] Cross-sectional Low 14,680 All Inpatient 233 205 Dec-1991/
Mar-1992
Honduras La Mosquita,
Bulnes, Palacios
[41] Cross-sectional Low 115 All Outpatient 34‡ 16 Jan-1999/
Mar-2000
5
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Table 2 – Meta-analyzed estimates of the incidence
of malaria episodes in published literature from
highly endemic areas (1000 person-years).
Ages Rate (95% CI) Person-
years
All ages (all study designs) 202.9 (180.9–224.9) 113,761
0–4 y 325.8 (50.4–601.2) 6,875
5–14 y 177.4 (89.2–265.5) 19,944
414 y 50.6 (37.2–64.0) 86,702
All ages (only prospective
studies with active case
detection)
409.0 (263.1–554.9) 60,470
All ages (only outpatient) 104.0 (81.4–126.5) 62,200
V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 6 9 – 7 9 73highest mortality rate followed by Guyana and French Guiana.
Mexico and Argentina reported no deaths due to malaria in the
years considered (Table 4). The pooled mortality estimate from
identiﬁed prospective studies [43,44] done in highly endemic
areas was 65.8/100,000 person-years (95% CI 43.4–88.2). Table 5
presents pooled mortality estimates by year for the whole region.
The highest CFR was reported in the Dominican Republic,
with 0.6% (95% CI 0.48–0.73). In the remaining countries, the CFR
was lower than 0.1% (data not shown). Because of the scarcity of
information on the use of health resources in the management of
malaria cases, a meta-analysis was not performed. Four studies
[26,43,49,50] reported a median length of stay of 4 days (range 3.3–
6.0 days).
Malaria Epidemiology in Brazil
Brazil has complete, online public information about malaria
hospitalizations, mortality, and incidence by age [13]. Data from
this source pertaining to the same period were analyzed and
shown separately. Malaria incidence from Brazilian studies done
in endemic areas in children younger than 5 years was 40
episodes/1000 person-years (95% CI 0–104.0). In persons older
than 14 years, the rate was 292.9 episodes/1000 person-years (95%
CI 124.8–461.1). Analysis of ofﬁcial Brazilian public health system
online database (DataSUS) data on the incidence rates across
regions showed heterogeneity, with high incidence rates in the
Northern Region, including the states of Acre, Amapá, Amazonas,
Pará, Rondônia, Roraima, and Tocantins (35 episodes/1000 pop-
ulation), and lower rates in the Central West Region, including
the states of Goiás, Mato Grosso, Mato Grosso do Sul, and Distrito
Federal (5 episodes/1000 population), and rates less than 1
episode/1000 persons in the remaining regions. The pooled
incidence rate of hospitalizations was 34.7 /1000 population per
year regardless of age (95% CI 28.45–40.96). P. vivax accounted for
35.4% of all malaria hospitalizations (95% CI 30.4–40.52).
Information on incidence by hospitalization status, proportion
of malaria admissions out of the total, slides analyzed, percent-
age of slides taken in health facilities that tested positive, para-
site species distribution, and patterns of circulation of Plasmodium
species strains over time is not shown, but available on demand.Discussion
This study represents the ﬁrst systematic review and meta-
analysis of malaria burden in LAC, synthesizing data from
prospective studies and ofﬁcial data from 21 countries. We found
an estimated pooled incidence of 409.0 malaria edpisodes/1000
person-years from prospective studies and 10.4/1000 person-
years estimated from ofﬁcial sources. The pooled incidence
reported by prospective studies is 40-fold that calculated on the
Study ID (data period)  n/N Incidence (95% Confidence Interval) per 1,000 person-years  Weight* (%)
Richards 1993 (1990-1) 70/341 205.3 (157.2 - 253.4) 7.8
Salcedo 2000 (1991) 655/840 779.8 (720.0 - 839.5) 7.7
Sempértegui 1994 (1991) 46/198 232.3 (165.2 - 299.5) 7.7
Valero 1993 (1991-2) 242/721 335.6 (293.4 - 377.9) 7.8
Duarte 2004 (1996-7) 101/187 540.1 (434.8 - 645.4) 7.5
Ropper 2000 (1997-8) 1369/1400 977.9 (926.1 – 1029.6) 7.8
Magris 2007 (1999-2000) 196/1049 186.8 (160.7 - 213.0) 7.8
Da Silva 2006 (2000) 26/157 165.6 (101.9 - 229.3) 7.7
Da Silva 2006 (2001) 17/207 82.1 (43.1 - 121.2) 7.8
Da Silva 2006 (2002) 63/105 600.0 (451.8 - 748.2) 7.2
Hill 2007 (2003) 72/622 115.8 (89.0 - 142.5) 7.8
Da Silva-Nunez 2006 (2004) 337/467 721.6 (644.6 - 798.7) 7.7
Da Silva-Nunez 2008 (2004-5) 195/489 398.8 (342.8 - 454.7) 7.7
409.0 (263.1– 554.9) delooP
10005000
Fig. 2 – Malaria incidence in highly endemic areas (1990–2009). Prospective studies with active case detection meta-analysis.
*From random-effects meta-analysis.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 6 9 – 7 974basis of cases reported by ministries of health, depicting the
difﬁculty of drawing adequate estimates of the real disease burden.
The most likely reason for this huge difference is that most
prospective studies were carried out in highly endemic areas in
the context of active case detection, whereas ofﬁcial information
is derived from areas of moderate or high risk for a given country
or region, mostly coming from passive surveillance and much
more prone to underreporting of cases. For example, Uniﬁed
Health System (SUS, Sistema Único de Saúde) data in Brazil show
that in most endemic areas such as Acre or Roraima, the Annual
Parasitic Index registered for 2010 was less than 50 cases/1000
persons [13], still much lower than the pooled estimate from
studies in regions with active detection. Indeed, the World
Malaria Report 2011 highlights the presence of severe under-
reporting of cases in many continents [2].
In addition, it is important to consider that most of the
published studies identiﬁed were relatively old. Pooled ﬁgures
of incidence, species distribution, or mortality from meta-
analyses help in making meaningful comparisons with other
geographical regions and over time [2]. The upper and lower
bounds of summary estimates probably represent with the least
uncertainty the range within which the true estimate lies. Other
malaria meta-analyses that reported incidence or prevalence as
pooled estimates have been published, [51,52] and endemicity
maps for LAC exist. [53,54] PAHO online data also show that the
incidence and the Annual Parasitic Indexes vary widely over time
and space. The present work, however, adds relevant information
as age distribution.
Brazil accounted for most of the cases in the region followed
by Colombia, Peru, and Venezuela, highlighting the higher bur-
den of cases in the Amazon rainforest (shared by Bolivia, Brazil,
Colombia, Ecuador, French Guiana, Guyana, Peru, Suriname, and
Venezuela). There were an estimated 216 million episodes of
malaria worldwide in 2010, of which approximately 81% were in
the African Region, mostly due to P. falciparum [2]. In LAC,
however, the most common parasite species was P. vivax,
accounting for 77% of the cases in most of the countries, except
in the Dominican Republic, Colombia, French Guiana, Guyana,
Haiti, and Suriname.
Our estimated mortality was considerably lower in LAC at 6/
100,000 person-years compared with that in Africa, where it was
estimated to be 84.3/100,000 person-years in 2010 [2] and con-
sistent with Murray et al.’s [1] analyses regarding the relatively
very small contribution of LAC deaths to the global mortality
burden of disease. An estimated 86% of the deaths by malaria in
the world occur in children younger than 5 years. Africa isdisproportionately affected, with 91% of the deaths occurring in
those younger than 5 years, compared with 29% in the Americas
[2].
In the Americas, mortality decreased by 55% between 2000
and 2010, probably because of the impact of disease control
programs [2]. The peak number of malaria cases in the region
was reported in 1994, with approximately 1.3 million cases
registered. After 1998, the total number of cases continued
declining, with the lowest values of 7/1000 persons-years at risk
in 2010, reﬂecting the effectiveness of the regional Roll Back
Malaria Initiative [2]. Because the global malaria control strategy
was adopted in 1992, the 21 LAC countries with varying degrees
of active malaria transmission implemented three control strat-
egies in their national programs: 1) early diagnosis and prompt
treatment; 2) planning and implementation of selective and
sustainable preventive measures, including vector control and
insecticide-treated bednets; and 3) early detection, containment,
and prevention of epidemics. In addition, local capacities in basic
and applied research were strengthened to permit and promote
the regular assessment of a country’s malaria situation, partic-
ularly the ecological, social, and economic determinants [55].
These strategies might explain the decrease in cases observed in
the last decade (Fig. 4).
Most of the cases occurred in restricted areas, and were often
related with activities such as mining, hydroelectric dam build-
ing, or wood extraction, for which speciﬁc and effective control
programs are needed. The naive, nonimmune individuals, mostly
working men with their bodies exposed to mosquito bites, are
usually the population most affected (due to the hot and humid
weather, and men working full time). In addition, in the last
decade, there was a sharp increase in laboratory access in the
Amazon region, with consequent decrease in the time to diag-
nosis and treatment of the disease. In the past, the conﬁrmation
of the malaria diagnosis by blood slides was done mainly for
highly suspicious cases, leading to a relatively high percentage of
positive blood slides. It is possible that in more recent years,
improvements in the availability and access of malaria diagnostic
tests performed for people with much lower likelihood of having
malaria could have resulted in a much lower slide positivity rate.
PAHO databases hold detailed country-speciﬁc epidemiologic
information on malaria, for the last 20 years [56].
The availability and adoption of artemisinin combination
therapies by national malaria control programs to treat P.
falciparum malaria in the last decade in most LAC countries also
led to the decrease in malaria deaths. The smaller number of
deaths reported by the Global Malaria program could also be
Incidence  
Fig. 3 – Population-wide pooled incidence quintiles by country (per 1000 person-years) and species distribution (ofﬁcial
Ministry of Health data, 1990–2009). This map does not reﬂect endemic areas within a country, but rather ofﬁcially registered
cases relating to the country’s total population for the years considered.
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found in our meta-analysis. P. vivax causes a more clinically
benign form of malaria, leading to a lower mortality rate than in
regions where P. falciparum predominates. It can cause compli-
cated and severe disease, however, as per clinical criteria(thrombocytopenia, bleeding, and other symptoms) in particular
populations such as in pregnant women, and severe cases have
been reported in LAC [57–61]. P. vivax thus carries a high burden
of disease in terms of morbidity in LAC according to our pooled
estimates. Underreporting of deaths to the health system may
Fig. 4 – Pooled incidence from endemic areas (API) in Latin America and Caribbean, from ofﬁcial sources (1990–2008). Spikes
denote 95% conﬁdence intervals. API, Annual Parasitic Index, calculated as the number of conﬁrmed cases per population at
moderate and high risk, per 1000 person-years.
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of P. vivax is possible until an effective vaccine is available,
particularly because of the toxic proﬁle of the currently available
antirelapsing drugs.Table 3 – Pooled percentage (%) of malaria parasites spec
Country P. vivax P. m
Argentina 99.88 (99.8–99.94) 0.04
Belize 97.41 (95.91–98.57) 0.04
Bolivia 91.48 (89.44–93.31) 0
Brazil 72.61 (68.52–76.51) 0.08
Colombia 62.72 (59.82–65.58) 0.03
Costa Rica 99.42 (98.95–99.75) 0.01
The Dominican Republic 0.38 (0.23–0.57) 0.02
Ecuador 72.59 (66.63–78.18) 0
El Salvador 99.67 (99.52–99.79) 0.01
French Guiana 26.94 (19.76–34.79) 1.39
Guatemala 97.32 (96.84–97.76) 0.01
Guyana 47.82 (45.34–50.31) 0.03
Haiti 0 (0–0.01) 0
Honduras 96.90 (96.13–97.58) 0
Mexico 99.28 (99.02–99.5) 0
Nicaragua 91.52 (89.92–92.99) 0
Panama 90.90 (87.34–93.91) 0.01
Paraguay 99.49 (99.11–99.76) 0.01
Peru 83.65 (78.59–88.15) 0.02
Suriname 9.99 (7.46–12.85) 5.25
Venezuela 81.73 (79.47–83.88) 0.09
MoH, Ministry of Health.The present systematic review and meta-analysis provides
valuable information regarding malaria burden from ofﬁcial
reports and articles published in peer-reviewed journals in LAC,
particularly on incidence, information that is not available fromies by country (1990–2008) from MoH ofﬁcial data.
alariae P. falciparum Mixed
(0.01–0.08) 0.12 (0.06–0.2)
(0.01–0.08) 2.54 (1.38–4.04)
(0–0) 8.24 (6.49–10.17) 0.39 (0.23–0.6)
(0.05–0.13) 26.69 (22.63–30.96) 1.06 (0.87–1.26)
(0.01–0.05) 36.46 (33.71–39.25) 0.72 (0.45–1.05)
(0–0.02) 0.44 (0.28–0.63) 0.18 (0.09–1.3)
(0–0.03) 99.61 (99.42–99.77) 0.01 (0–0.04)
(0–0) 27.41 (21.82–33.37)
(0–0.02) 0.32 (0.2–0.46)
(0.67–2.35) 70.53 (62.81–77.69) 0.88 (0.65–1.14)
(0–0.02) 2.58 (2.14–3.05) 0.09 (0.03–0.17)
(0–0.09) 50.43 (47.4–53.45) 1.27 (0.71–1.97)
(0–0) 100 (99.99–100)
(0–0) 3.01 (2.36–3.74) 0.17 (0.11–0.24)
(0–0) 0.79 (0.55–1.06)
(0–0) 8.48 (7.01–10.08)
(0–0.03) 9.08 (6.07–12.63) 0.04 (0.02–0.06)
(0–0.03) 0.47 (0.21–0.83) 0.02 (0.01–0.05)
(0.01–0.03) 16.28 (11.78–21.36)
(3.57–7.23) 83.53 (78.94–87.65) 0.59 (0.42–0.8)
(0.06–0.14) 17.75 (15.53–20.09) 0.59 (0.35–0.88)
Table 4 – Pooled estimates of malaria mortality in
Latin America and Caribbean by country, 1990–
2009, from ofﬁcial MoH sources (per 1000 person-
years).
Country Rate (95% CI) Person-years
Argentina 0 (0–0) 39,189,880
Belize 0.22 (0.05–0.4) 2,922,949
Bolivia 0.15 (0.08–0.21) 41,815,394
Brazil 0.32 (0.26–0.39) 788,433,774
Colombia 0.24 (0.18–0.31) 201,192,440
Costa Rica 0.04 (0.01–0.07) 19,462,989
The Dominican Republic 0.13 (0.09–0.16) 135,179,325
Ecuador 0.01 (0–0.02) 98,006,425
El Salvador 0.01 (0–0.02) 60,285,129
French Guiana 1.15 (0.43–1.87) 1,560,447
Guatemala 0.12 (0.05–0.19) 57,024,289
Guyana 2.19 (1.31–3.07) 5,702,374
Haiti 0.45 (0.29–0.61) 68,307,551
Honduras 0.01 (0–0.02) 64,372,819
Mexico 0 (0–0) 485,925,763
Nicaragua 0.18 (0.12–0.23) 80,169,956
Panama 0.03 (0.01–0.04) 52,479,404
Paraguay 0.02 (0–0.04) 31,974,670
Peru 0.22 (0.15–0.29) 147,601,049
Suriname 7.13 (4.56–9.69) 1,599,778
Venezuela 0.27 (0.19–0.34) 112,942,818
All LAC 0.06 (0.06–0.07) 2,496,149,223
CI, conﬁdence interval; LAC, Latin America and Caribbean; MoH,
Ministry of Health.
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were omitted. The inclusion of ofﬁcial and published data allows
a more complete picture of the burden of disease in LAC,
including incidence and mortality, than by using ofﬁcial data
only. Our study also describes the most common malaria parasite
species in LAC, mortality, CFR, and hospitalization, which wasTable 5 – Malaria mortality in LAC by year (100,000
persons/y).
Year Rate
(95% CI)*
No. of
countries
Total person-
years
1990 0.19 (0.11–0.27) 15 113,585,835
1991 0.24 (0.16–0.32) 16 81,668,005
1992 0.13 (0.05–0.22) 10 41,962,276
1993 0.04 (0.00–0.17) 3 7,475,912
1994 0.11 (0.03–0.19) 5 25,541,752
1995 0.16 (0.02–0.3) 6 33,879,939
1996 0.26 (0.13–0.39) 8 78,616,582
1997 0.33 (0.12–0.54) 6 24,145,408
1998 0.12 (0.07–0.17) 17 196,084,569
1999 0.13 (0.08–0.18) 17 173,352,256
2000 0.10 (0.06–0.14) 18 204,943,289
2001 0.09 (0.06–0.12) 20 210,429,863
2002 0.09 (0.06–0.12) 20 181,035,762
2003 0.07 (0.04–0.09) 19 307,081,045
2004 0.06 (0.03–0.08) 20 247,555,957
2005 0.08 (0.05–0.11) 20 256,019,124
2006 0.09 (0.05–0.13) 20 101,340,883
2007 0.1 (0.06–0.14) 20 120,927,375
2008 0.05 (0.02–0.08) 18 90,503,391
* CI, conﬁdence interval; LAC, Latin America and Caribbean.previously missing in ofﬁcial data sources and highly relevant
when considering health resource utilization as well as the
implementation and evaluation of malaria control programs [62].
The main limitations of this review include the high risk of
bias of many of the included incidence studies, mainly due to
selection bias; the lack of population-based and well-designed
epidemiological studies; and the important degree of heteroge-
neity evidenced in the information retrieved regarding designs
and objectives of the different studies. Data on incidence, how-
ever, were meta-analyzed only in the case of prospective, active
case detection high-quality studies, and random-effects models
were selected. Because these prospective studies were done
mainly in high transmission areas, their estimates are incon-
sistent with those coming from ofﬁcial Ministry of Health data,
which may be pertinent to broader geographic areas. Summary
epidemiologic information from highly endemic areas is mean-
ingful to accurately determine the burden of the disease, in order
to improve control programs. Another shortcoming detected was
the paucity of information on mortality rates and age distribution
of cases caused by Plasmodium species.
Considerable changes have taken place in the region, politi-
cally and socioeconomically, both very important for health and
health care. National and international awareness of the malaria
problem has increased in the period analyzed and control pro-
grams were undertaken and fortunately, progress has been made,
especially since 2005. Updating global maps of malaria endemic-
ity is a priority because it enables a better-informed resource
allocation. Future research is needed to assess the economic and
social impact of malaria, and to supply detailed information,
regarding incidence, prevalence, costs, work absence, and social
burden of malaria, that will improve our knowledge and manage-
ment of the disease.
In conclusion, although this study shows a decrease in the
number of cases and deaths during the last decade and a
decrease in the incidence of disease caused by P. falciparum,
malaria remains an important health problem in LAC.Acknowledgments
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[13] DataSUS Brazil. Information system of the Brazilian Ministry of Health
(DATASUS). 2009. Available from: http://datasus.saude.gov.br. [Accessed
March 20, 2011].
[14] Pan American Health Organization. Malaria in the Americas: time
series epidemiological data from 2000 to 2007. Washington, DC: Pan
American Health Organization, 2008.
[15] Pan American Health Organization. Core Health Data System - Glossary,
2013: Available from: http://www.paho.org/hq/index.php?option=com_
content&view=article&id=9074%3Acore-health-data-system-glossary&
catid=1775%3Ahia-basic-health-indicators&lang=en. [Accessed, March 31,
2013].
[16] von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) statement:
guidelines for reporting observational studies. Lancet 2007;370:1453–7.
[17] Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and
susceptibility to bias in observational studies in epidemiology: a
systematic review and annotated bibliography. Int J Epidemiol
2007;36:666–76.
[18] Berra S, Elorza-Ricart JM, Estrada MD, Sánchez E. [A tool (corrected) for
the critical appraisal of epidemiological cross-sectional studies]. Gac
Sanit 2008;22:492–7.
[19] Fowkes FG, Fulton PM. Critical appraisal of published research:
introductory guidelines. BMJ 1991;302:1136–40.
[20] Wong W, Cheung C, Hart G. Development of a quality assessment tool
for systematic reviews of observational studies (QATSO) of HIV
prevalence in men having sex with men and associated risk
behaviours. Emerg Themes Epidemiol 2008;5:23.
[21] Higgins JP1, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327:557–60.
[22] Hill N, Lenglet A, Arnéz AM, Carneiro I. Plant based insect repellent and
insecticide treated bed nets to protect against malaria in areas of early
evening biting vectors: double blind randomised placebo controlled
clinical trial in the Bolivian Amazon. BMJ 2007:1023.
[23] Camargo LM, Noronha E, Salcedo JM, et al. The epidemiology of malaria
in Rondonia (Western Amazon region, Brazil): study of a riverine
population. Acta Tropica 1999;72:1–11.
[24] da Silva AR, Tauil PL, Bastos Júnior JL, et al. Aspects of the focal
transmission of malaria in the Island of Sao Luis, Maranhao [in
Portuguese]. Rev Soc Bras Med Trop 2006;39:250–4.
[25] Da Silva-Nunes M, Codeço CT, Malafronte RS, et al. Malaria on the
Amazonian frontier: transmission dynamics, risk factors, spatial
distribution, and prospects for control. Am J Trop Med Hyg 2008;79:624–35.
[26] Duarte EC, Gyorkos TW, Pang L, Abrahamowicz M. Epidemiology of
malaria in a hypoendemic Brazilian Amazon migrant population: a
cohort study. Am J Trop Med Hyg 2004;70:229–37.
[27] Jarude R, Trindade R, Tavares-Neto J. Malária em grávidas de uma
maternidade pública de Rio Branco (Acre, Brasil). Rev Bras Ginecol
Obstet 2003;25:149–54.
[28] Ribeiro MC, Gonçalves Eda G, Tauil PL, Silva AR. Aspectos
epidemiológicos de um foco de malária no município de São Luis, MA.
Rev Soc Bras Med Trop 2005;38:272–4.[29] Salcedo JM, Camargo EP, Krieger H, et al. Malaria control in an agro-
industrial settlement of Rondônia (Western Amazon region, Brazil).
Mem Inst Oswaldo Cruz 2000;95:139–45.
[30] Silva AR, Tauil PL, Bastos Jr JL, et al. Aspectos da transmissão focal de
malária na Ilha de São Luis, Maranhão. Rev Soc Bras Med Trop
2006;39:250–4.
[31] Silva-Nunes MD, Malafronte Rdos S, Luz Bde A, et al. The Acre
Project: the epidemiology of malaria and arthropod-borne virus
infections in a rural Amazonian population. Cad Saúde Pública
2006;22:1325–34.
[32] Ochoa J, Osorio L. Epidemiología de malaria urbana en Quibdó, Chocó.
Biomédica (Bogotá) 2006;26:278–85.
[33] Soto J, Toledo J, Luzz M, et al. Randomized, double-blind, placebo-
controlled study of malarone for malaria prophylaxis in non-immune
Colombian soldiers. Am J Trop Med Hyg 2006;75:430–3.
[34] Valero MV, Amador LR, Galindo, et al. Vaccination with SPf66, a
chemically synthesised vaccine, against Plasmodium falciparum malaria
in Colombia. Lancet 1993:705–10.
[35] Sempértegui F, Estrella B, Moscoso J, et al. Safety, immunogenicity and
protective effect of the SPf66 malaria synthetic vaccine against
Plasmodium falciparum infection in a randomized double-blind placebo-
controlled ﬁeld trial in an endemic area of Ecuador. Vaccine
1994:337–42.
[36] San Sebastián M, Játiva R, Goicolea I. Epidemiology of malaria
in the Amazon basin of Ecuador. Rev Panam Salud Pública 2000;7:
24–8.
[37] Hustache S, Nacher M, Djossou F, Carme B. Malaria risk factors in
Amerindian children in French Guiana. Am J Trop Med Hyg
2007;76:619–25.
[38] Carles G, Bousquet F, Raynal P, et al. Pregnancy and malaria: a study of
143 cases in French Guyana [in French]. J Gynecol Obstet Biol Reprod
1998;27:798–805.
[39] Richards FO Jr, Klein RE, Flores RZ, et al. Permethrin-impregnated bed
nets for malaria control in northern Guatemala: epidemiologic impact
and community acceptance. Am J Trop Med Hyg 1993;49:410–8.
[40] Bawden MP, Slaten DD, Malone JD. Falciparum malaria in a displaced
Haitian population. Trans R Soc Trop Med Hyg 1995;89:600–3.
[41] Aguilar CJ, Bú Figueroa E, Alger J. Caracterízación clínica y
epidemiológica de la malaria en una comunidad endémica de
Honduras. Rev Méd Hondur 2004;72:178–86.
[42] Guthmann JP, Llanos-Cuentas A, Palacios A, Hall AJ. Environmental
factors as determinants of malaria risk: a descriptive study on the
northern coast of Peru. Trop Med Int Health 2002;7:518–25.
[43] Quino AH, Durand VS, Maguiña Vargas CP. Malaria por Plasmodium
falciparum en adultos hospitalizados de Iquitos: aspectos clínicos y
epidemiológicos. Acta Med Peru 2001;18:52–7.
[44] Roper MH, Torres RS, Goicochea CG, et al. The epidemiology of malaria
in an epidemic area of the Peruvian Amazon. Am J Trop Med Hyg
2000;62:247–56.
[45] Magris M, Rubio-Palis Y, Alexander N, et al. Community-randomized
trial of lambdacyhalothrin-treated hammock nets for malaria control
in Yanomami communities in the Amazon region of Venezuela. Trop
Med Int Health 2007;12:392–403.
[46] Malaria atlas project. Available from: http://www.map.ox.ac.uk/explore/
about-malaria/malaria-endemicity/. [Accessed November 30, 2009].
[47] Carmona-Fonseca J, Maestre A. Incidencia de las malarias gestacional,
congénita y placentaria en Urabá (Antioquia, Colombia), 2005–2007
[Incidence of gestational, congenital and placental malaria in Urabá
(Antioquia, Colombia), 2005-2007]. Rev Col Obstet Ginecol
2009;60:19–33.
[48] Ramal Asayag C, Pinedo Iglesias P. Malaria en gestantes entre marzo
del 2002 y julio del 2003: experiencia en el Hospital Regional de Loreto,
Perú. Acta Med Peru 2008;25:220–3.
[49] Bonnlander H, Rossignol AM, Rossignol PA. Malaria in central Haiti: a
hospital-based retrospective study, 1982-1986 and 1988-1991. Bull Pan
Am Health Organ 1994;28:9–16.
[50] Gonzalez LM, et al. Caracteristicas clinico-epidemiologicas de 291
pacientes hospitalizados por malaria en Medellin (Colombia). Acta Méd
Colomb 2000;25:163–70.
[51] Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship
between anti-merozoite antibodies and incidence of Plasmodium
falciparum malaria: a systematic review and meta-analysis. PLoS Med
2010;7:e1000218.
[52] Chico RM, Mayaud P, Ariti C, et al. Prevalence of malaria and sexually
transmitted and reproductive tract infections in pregnancy in sub-
Saharan Africa: a systematic review. JAMA 2012;307:2079–86.
[53] Gething PW, Elyazar IR, Moyes CL, et al. A long neglected world malaria
map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012;6:
e1814.
[54] Gething PW, Patil AP, Smith DL, et al. A new world malaria map:
Plasmodium falciparum endemicity in 2010. Malar J 2011;10:378.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 6 9 – 7 9 79[55] Pan American Health Organization. Salud en las Américas. Health in
the Americas. In: Volumen Regional. Washington, DC: Organización
Panamericana de la Salud, 2007:2 v.
[56] Pan American Health Organization. Interactive malaria statistics. Available
from: http://www.paho.org/hq/index.php?option=com_content&view=
article&id=2632&Itemid=2130&lang=en. [Accessed March 31, 2013].
[57] Severe malaria. Trop Med Int Health 2014;19(Suppl. 1):7–131.
[58] Lacerda MV, Fragoso SC, Alecrim MG, et al. Postmortem chara-
cterization of patients with clinical diagnosis of Plasmodium vivax
malaria: to what extent does this parasite kill? Clin Infect Dis 2012;55:
e67–74.[59] Andrade BB, Reis-Filho A, Souza-Neto SM, et al. Severe Plasmodium
vivax malaria exhibits marked inﬂammatory imbalance. Malar J
2010;9:13.
[60] Rodriguez-Morales AJ, Benitez JA, Arria M. Malaria mortality in
Venezuela: focus on deaths due to Plasmodium vivax in children. J Trop
Pediatr 2008;54:94–101.
[61] Rodriguez-Morales AJ, Sánchez E, Vargas M, et al. Anemia and
thrombocytopenia in children with Plasmodium vivax malaria. J Trop
Pediatr 2006;52:49–51.
[62] Nabarro DN, Tayler EM. The “roll back malaria” campaign. Science
1998;280:2067–8.
